leisure time -WSS

leisure time

author：explore 2025-10-01 20:16:30 - browse：24437

Transparent plastic divider on the reception desk in the hospital admission department with red lettering emergency. — Adobe

QuidelOrtho has recalled nearly 8,000 potentially faulty blood tests meant to help doctors quickly determine whether a patient is having a heart attack.

The tests inaccurately showed low levels of troponin, a protein that indicates damage to the heart. A false negative could lead doctors to mistakenly conclude their patient is not having a heart attack, delaying diagnosis or treatment when time is of the essence.

The device maker, which also sells products like the QuickVue Covid-19 antigen test, sent letters to health systems in May telling them to immediately stop using the test. The Food and Drug Administration classified the recall as serious, because problems with the product could result in serious injury or death. QuidelOrtho has reported 41 complaints, but no injuries or deaths so far.

The tests, which use either a blood or plasma sample, promise to return results in under half an hour. They are used in emergency rooms to triage patients suspected of having a heart attack.

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

The FDA said the patients most at risk are those with zero or abnormal heart attack symptoms, for whom a diagnosis would be easy to miss without an accurate lab test.

The company advised using a different testing method to detect heart attacks. If none are available, doctors should be extra wary of the blood panel’s readings, perform multiple tests to confirm low troponin levels, and also reference data from EKGs and other imaging.

San Diego-based QuidelOrtho said the error is due to a “raw material issue” in its recall record. The issue caused the test to falsely pick up 30% less troponin than is present. The company did not respond to STAT’s request for more information on the error.

The test maker’s last serious recall was in 2021 for reports of false negatives from its Lyra PCR Covid-19 test when used with certain lab equipment. The notice impacted more than 18,000 test kits.

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

focus

WSS

Protect nursing home residents from future pandemics

The world needs the new pandemic treaty

STAT Summit: Ending the crisis of Black deaths in the U.S.

Why we need mandatory labeling of GMO products

UnitedHealth, Optum discontinue NaviHealth name

Merck, Daiichi strike cancer drug pact worth up to $22 billion

entertainment

leisure time

Related: With Wegovy and Ozempic’s success, can device makers keep up in the race to treat obesity?

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

State Dept. review finds Biden bears some blame for Afghanistan failures

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Medical records are filled with copy

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Drug repurposing or repositioning? The language matters

J&J reports mixed data on next

After affirmative action ruling, medical educators look to 'holistic review'

Why we need mandatory labeling of GMO products

hotspot

Bird flu makes raw milk dangerous to consume, mouse study finds

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Protect nursing home residents from future pandemics

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

STAT Readout Newsletter: Biotech news today

focus

hotspot

focus

focus